RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy-Reference-Cited by-同舟云学术

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy

Published:2017-02-01 Issue:2 Volume:3 Page:227
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Fumagalli Debora¹,Venet David¹,Ignatiadis Michail¹,Azim Hatem A.¹,Maetens Marion¹,Rothé Françoise¹,Salgado Roberto¹,Bradbury Ian²,Pusztai Lajos³,Harbeck Nadia⁴,Gomez Henry⁵,Chang Tsai-Wang⁶,Coccia-Portugal Maria Antonia⁷,Di Cosimo Serena⁸,de Azambuja Evandro⁹,de la Peña Lorena¹⁰,Nuciforo Paolo¹¹,Brase Jan C.¹²,Huober Jens¹³,Baselga José¹⁴,Piccart Martine¹⁵,Loi Sherene¹⁶,Sotiriou Christos¹¹⁵

Affiliation:

1. Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

2. Frontier Science Scotland, Kincraig, Inverness-shire, Scotland

3. Breast Medical Oncology Section, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut

4. Breast Center, Department of Obstetrics and Gynecology, University of Munich, Munich, Germany

5. Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

6. Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan

7. Clinical Trial Department, Eastleigh Breast Care Centre, Pretoria, South Africa

8. Department of Oncology, Istituto Nazionale Tumori, Milan, Italy

9. Breast European Adjuvant Study Team, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

10. SOLTI–Breast Cancer Research Group, Barcelona, Spain

11. Molecular Oncology Laboratory, Vall d’Hebron Institute of Oncology, Barcelona, Spain

12. Novartis Pharmaceutical, Basel, Switzerland

13. Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany

14. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

15. Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

16. Division of Cancer Medicine and Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference48 articles.

1. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.;Baselga;N Engl J Med,2012

2. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.;Blackwell;J Clin Oncol,2012

3. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.;Baselga;Lancet,2012

4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.;Gianni;Lancet Oncol,2012

5. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.;Robidoux;Lancet Oncol,2013

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab;International Journal of Molecular Sciences;2024-08-27

2. iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics data;BMC Bioinformatics;2024-06-19

3. In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment;Breast Cancer Research;2024-06-12

4. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer;JAMA Oncology;2024-05-01

5. Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future;ESMO Gastrointestinal Oncology;2024-03